Skip to main content
TipRanks
Go Ultimate75% OFF

BrainAurora Medical Technology Limited (6681) AI Stock Analysis

4 Followers
HK:6681

BrainAurora Medical Technology Limited

(HKEX:6681)

Select Model
Rating:44Neutral
Price Target:HKD 1.50â–²(9.49% Upside)
Action:reiterated
Date:11/04/26

The score is primarily constrained by substantial losses, persistent cash burn, and high leverage. Moderate technical momentum provides some support, but the negative P/E and lack of profitability keep the overall score low.

Positive Factors
Strong Revenue GrowthRapid revenue expansion indicates increasing adoption of the company’s neurological-health products and solutions. If this growth is sustained, a larger revenue base could improve operating leverage, support broader commercialization, and strengthen the company’s position in its target medical technology markets.
Negative Factors
Deep Net LossesThe company remains far from breakeven, with operating costs substantially exceeding its current revenue base despite strong sales growth. Persistent large losses weaken financial resilience, consume capital, and make future profitability dependent on significant cost control and continued expansion.

BrainAurora Medical Technology Limited (6681) vs. iShares MSCI Hong Kong ETF (EWH)

-100%-75%-50%-25%0%25%HK:6681-78.79%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.86B
Dividend Yield
―
Average Volume (3M)
102.64M
Price to Earnings (P/E)
-4.8
Beta (1Y)
0.84
Revenue Growth
―
EPS Growth
―
Country
Hong Kong
Employees
165
Sector
General
Sector Strength
55
Industry
Biotechnology

BrainAurora Medical Technology Limited Business Overview & Revenue Model

Company Description

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evalua...

BrainAurora Medical Technology Limited Financial Statement Overview

Summary

Revenue growth is strong, but severe operating losses, deeply negative cash flow, high leverage, and thin equity place financial performance at the minimum score.

Income Statement

25Negative

Balance Sheet

15Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue239.86M220.05M122.31M67.20M11.29M2.30M
Gross Profit103.21M89.45M54.01M32.06M3.30M1.30M
EBITDA-256.54M-264.78M-149.39M-317.63M-470.81M-689.82M
Net Income-322.47M-314.86M-198.28M-359.08M-502.45M-697.84M
Balance Sheet
Total Assets1.05B733.20M599.50M394.85M418.09M371.30M
Cash, Cash Equivalents and Short-Term Investments658.44M531.78M343.88M57.58M287.22M323.74M
Total Debt556.24M565.76M388.28M364.07M328.14M308.76M
Total Liabilities629.79M637.69M1.06B727.03M1.51B1.05B
Stockholders Equity419.32M97.39M-463.65M-332.14M-1.09B-681.28M
Cash Flow
Free Cash Flow-74.67M-205.75M-167.24M-155.00M-119.74M-60.31M
Operating Cash Flow-67.88M-178.03M-149.49M-136.87M-100.68M-49.21M
Investing Cash Flow-105.33M-272.88M125.37M102.55M-334.46M-21.48M
Financing Cash Flow116.19M339.27M315.50M63.53M139.65M393.61M

BrainAurora Medical Technology Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.37

Price Trends

50DMA1.20Positive
100DMA1.41Negative
200DMA2.65Negative

Market Momentum

MACD0.09Negative
RSI53.21Neutral
STOCH47.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6681, the sentiment is Neutral. The current price of 1.37 is above the 20-day moving average (MA) of 1.26, above the 50-day MA of 1.20, and below the 200-day MA of 2.65, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 53.21 is Neutral, neither overbought nor oversold. The STOCH value of 47.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6681.

BrainAurora Medical Technology Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

HK:6681 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1521HK:152166NeutralHKD 4.23B50.743.02%―10.32%178.23%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HK:3347HK:334755NeutralHKD 40.89B-99.75-2.00%0.39%21.72%-169.67%
HK:2157HK:215753NeutralHKD 4.87B17.0017.36%―46.90%―
HK:6681HK:668144NeutralHKD 1.86B-4.75-124.83%―――
HK:1477HK:147743NeutralHKD 4.06B-27.56-3.44%―77.55%50.34%
HK:6622HK:662240UnderperformHKD 1.19B-4.86-14.41%―2.56%20.20%

* General Sector Average

Performance Comparison

-50%0%50%HK:6681HK:3347HK:1477HK:1521HK:2157HK:6622Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6681 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6681BrainAurora Medical Technology Limited1.37-5.10-78.83%
HK:3347Hangzhou Tigermed Consulting Co., Ltd. Class H36.82-4.23-10.30%
HK:1477Ocumension Therapeutics4.97-3.59-41.88%
HK:1521Frontage Holdings Corp.2.081.0193.93%
HK:2157Lepu Biopharma Co. Ltd. Class H2.70-3.31-55.07%
HK:6622Zhaoke Ophthalmology Ltd.2.17-1.31-37.64%

BrainAurora Medical Technology Limited Corporate Events

BrainAurora Wins First Beijing Approval for Depression Cognitive Assessment Device

Oct 27, 2026

BrainAurora Medical Technology has received a Class II Medical Device Registration Certificate from the Beijing Municipal Medical Products Administration for its standalone cognitive function assessment software for patients with depression. The prod...

BrainAurora defines optimal pediatric doses for cognitive digital therapeutics in major BMC Medicine study

Sep 9, 2026

BrainAurora Medical Technology has reported the publication of a major study in BMC Medicine that defines optimal digital training doses for children and adolescents with cognitive impairments using its Brain Function Information Management Platform....

BrainAurora’s Self-Adaptive Digital Therapy Shows Strong Schizophrenia Results

Sep 2, 2026

BrainAurora Medical Technology Limited has reported new clinical research results demonstrating the efficacy of its self-adaptive computerized cognitive remediation technology for schizophrenia. The study used the company’s Brain Function Information...

BrainAurora lifts revenue as it deepens push into AI cognitive digital therapeutics

Aug 28, 2026

BrainAurora Medical Technology Limited reported interim revenue of RMB119.9 million for the six months ended June 30, 2026, up 19.8% year on year, while its loss widened modestly, with total comprehensive expense at RMB134.6 million and an adjusted n...

BrainAurora Schedules Board Meeting to Approve Interim 2026 Results

Aug 18, 2026

BrainAurora Medical Technology Limited, a listed medical technology company incorporated in the Cayman Islands and traded on the Hong Kong Stock Exchange, operates through a group structure focused on healthcare innovation and related services. Its g...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026